Let’s Chat About…Atsena Therapeutics’ work in LCA
October 27, 2022 @ 1:00PM — 2:00PM Eastern Time (US & Canada) Add to Calendar
Join our conversation on Atsena Therapeutics’ work in LCA with Shannon Boye and Kara Fick
Let’s Chat About … Atsena Therapeutics’ work in LCA
Join us for an introduction to Atsena Therapeutics with Kara Fick, Head of Patient Advocacy, and Shannon Boye, Founder and Director. We’ll talk about Atsena’s approach to gene therapy and their ongoing work in LCA.
About Kara Fick
Kara is the head of Patient Advocacy and Medical Affairs at Atsena Therapeutics. She has been working as a patient advocate for rare disease in the biotech world for nearly a decade and is passionate about bringing the patient voice, perspective, and expertise to the table. At Atsena, Kara strives to bridge the gap between the science of innovative therapies and the daily needs of individuals living with rare diseases. She also works to better understand the current barriers to diagnosis, treatment, and management of rare disease and ways that we can better address those hurdles with patients and clinicians alike. Kara holds a BS in Biomedical Sciences from Texas A&M University.
About Shannon Boye
Dr. Shannon E. Boye is a Professor and Associate Chief of the Division of Cellular and Molecular Therapy in the University of Florida’s Department of Pediatrics. She received her BS in marine biology with a minor in chemistry from Fairleigh Dickinson University in 2001. She graduated with a PhD in Neuroscience from the University of Florida in 2006. Her thesis work involved developing viral vectors for the treatment of retinal disease, specifically GUCY2D Leber Congenital Amaurosis (LCA1). Dr. Boye has authored over 60 peer-reviewed manuscripts, multiple textbook chapters, is actively involved in grant and manuscript review, and is the recipient of several major awards. Shannon and her husband Sanford are the founders of Atsena Therapeutics.
About the "Let's Chat About..." Web Series
